Esperion Therapeutics, Inc.

ESPR11 Dec 2024
Healthcare
$3.84
-0.21 (-20.63%)
Lowest Today
$2.97
Highest Today
$3.89
Today’s Open
$3.84
Prev. Close
$3.83
52 Week High
$3.94
52 Week Low
$1.38
To Invest in Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

Healthcare
ESPR11 Dec 2024
-0.21 (-20.63%)
1M
3M
6M
1Y
5Y
Low
$2.97
Day’s Range
High
$3.89
2.97
52 Week Low
$1.38
52-Week Range
52 Week High
$3.94
1.38
1 Day
-
1 Week
-17.02%
1 month return
+21.07%
3 month return
+75%
6 month return
+5%
1 Year return
+116.72%
3 Years return
-39.82%
5 Years return
-93.92%
10 Years return
-
Institutional Holdings
Wasatch Advisors LP
11.85
BlackRock Inc
7.1
Vanguard Group Inc
6.62
BB Biotech AG Ord
5.05
Bellevue Group AG
5.05
Wasatch Ultra Growth
3.39
Two Seas Capital LP
3.34

Market Status

Fundamentals
Market Cap
754.64 mln
PB Ratio
98.42
PE Ratio
0
Enterprise Value
809.93 mln
Total Assets
205.8 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Organisation
Esperion Therapeutics, Inc.
Employees
240
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sheldon L. Koenig
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities